Wes Chapman | Amherst Partners
17982
page-template-default,page,page-id-17982,page-child,parent-pageid-15368,bridge-core-2.4.5,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,qode-child-theme-ver-1.0.0,qode-theme-ver-23.0,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive," ng-app="lscf-app

Wes Chapman

Operating Director

About Wes

Prior to joining Amherst as an Operating Director, Wes was President and CEO of Verdi Oncology, a medical oncology company dedicated to value-based cancer care, which he founded in 2016.

 

Wes has been a pioneer in the incorporation of advanced quality systems – lean/six sigma and ISO – into medical clinical practice. He is an expert in medical quality and value-based care reimbursement systems, teaching these subjects at Dartmouth and Vanderbilt.

 

Wes has an unbroken track record of strategic and operating excellence as a CEO and investor, with particular success in developing functional strategies to simultaneously grow revenues and improve profits. He has a proven ability to realize value from the companies he runs and/or invests in.

 

He is a graduate of Dartmouth College and the Tuck School of Business at Dartmouth and holds a Lean/Six Sigma Black Belt from the Thayer School of Engineering. Additionally, Wes has extensive experience in the development of real-world evidence in medical applications and all phases of clinical trials for both drugs and devices. He has extensive experience bringing new medical devices to market, FDA device approvals and in reimbursement for medical devices.

 

Prior to Verdi Oncology, Wes was an operating partner at Pharos Capital, the private equity group in Tennessee, with over $1 billion in capital invested and under management. In addition, he served as SVP of Strategy at Tennessee Oncology, as Chairman & CEO of M2S, Inc., and as a partner at the investment banking firms of Oppenheimer & Co. and Donaldson, Lufkin & Jenrette. He has extensive international experience, running major operations for Japanese investors in North America and extensive investment and operating experience in South America.